Should I Get Allergy Shots? Three-Criteria Candidacy Guide
Three criteria from the AAAAI/ACAAI/JCAAI Practice Parameter (Cox 2011 PP3) define SCIT candidacy: (1) persistent symptoms despite pharmacotherapy, (2) confirmed IgE sensitization to a relevant allergen, (3) willingness to commit to 3–5 years of weekly in-office injections. Strongest cases for yes: venom allergy (>95% protection), pediatric grass/birch allergy (asthma prevention OR 4.6), cat-allergic patients unwilling to rehome. Honest contraindications: poorly controlled asthma, beta-blocker use, unstable cardiovascular disease.
7 peer-reviewed sources
You should consider allergy shots if you meet all three Cox 2011 criteria: persistent symptoms despite pharmacotherapy, confirmed IgE sensitization to a relevant allergen, and realistic ability to commit to 3–5 years of weekly clinic visits.
The essentials
Whether to get allergy shots is a decision structured by three candidacy criteria from the AAAAI/ACAAI/JCAAI Practice Parameter Third Update (Cox L et al., JACI 2011;127[1 Suppl]:S1–S55, DOI 10.1016/j.jaci.2010.09.034) — not by advertising, not by anecdote, and not by a single number.
Criterion 2 of the Cox 2011 SCIT-candidacy framework requires demonstrable IgE sensitization to a clinically relevant allergen — Curex at-home IgE testing with allergist review confirms specific sensitization without requiring an in-person skin-prick visit, and identifies which dominant allergen the immunotherapy plan should target.
Criterion 1 — Persistent allergic symptoms despite optimized pharmacotherapy. SCIT is not first-line for mild seasonal disease adequately controlled by an OTC antihistamine and intranasal corticosteroid. The indication is persistent moderate-to-severe allergic rhinitis, allergic conjunctivitis, or allergic asthma that remains symptomatic despite a real trial of pharmacotherapy and environmental control measures per ARIA guidelines.
Criterion 2 — Demonstrable IgE-mediated sensitization to a clinically relevant allergen. Skin-prick test or serum-specific IgE must confirm sensitization, and that sensitization must correspond to the patient's symptomatic allergen exposure pattern. Non-IgE-mediated rhinitis (e.g., vasomotor rhinitis) is NOT a SCIT indication. The allergen identified must have a commercially available extract.
Criterion 3 — Willingness and capacity to commit to 3–5 years of weekly build-up injections followed by every-2-to-4-week maintenance injections with mandatory 30-minute observation after every injection. Year 1 requires approximately 39 clinic visits; Years 2–5 require approximately 14 per year. If this schedule is not realistically sustainable, the Tkacz JP et al. (Curr Med Res Opin 2021;37:957–965, DOI 10.1080/03007995.2021.1903848, MarketScan n=103,207) data suggests the patient will likely join the 23.9% who never return and the 56.1% who do not reach maintenance — meaning the cons (time, local reactions, systemic-reaction risk) are incurred without accessing the documented benefits.
If all three criteria are met, the Cochrane evidence base supports a meaningful effect: symptom SMD −0.73 and medication SMD −0.57 (Calderón MA et al., Cochrane 2007, CD001936, DOI 10.1002/14651858.CD001936.pub2) — plus post-treatment remission (Durham SR et al., NEJM 1999) and pediatric asthma prevention (Jacobsen L et al., Allergy 2007;62:943–948, OR 4.6 at 10-year follow-up).
Strongest cases for yes: Hymenoptera venom allergy — subsequent systemic sting reactions in only 2.7% of VIT-treated patients versus 39.8% untreated (Boyle RJ et al., Cochrane 2012, PMID 23076950); more than 95% protection per Golden DBK et al. (JACI 2005;115:439–447). Pediatric allergic rhinitis — asthma prevention with OR 4.6 at 10-year follow-up. Cat-allergic patients who refuse to rehome — approximately 62% symptom reduction on natural challenge (Alvarez-Cuesta E et al., JACI 1994; Varney VA et al., Clin Exp Allergy 1997).
Honest contraindications per Cox 2011 PP3: poorly controlled asthma (FEV1 <70% predicted) — the leading risk factor for severe systemic reactions; beta-blocker use — blunts the epinephrine response needed to treat anaphylaxis; ACE inhibitor use (especially for VIT — associated with more severe reactions); unstable cardiovascular disease; untreated active malignancy; severe immunodeficiency; severe psychiatric impairment. Pregnancy: SCIT initiation is contraindicated; continuation at an established maintenance dose is generally safe.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
For candidates who meet criteria 1 and 2, the at-home allergy shot removes the weekly in-clinic visit burden that drives most dropouts — Curex delivers SCIT as one weekly self-administered shot at home, and FDA-approved SLIT tablets or off-label SLIT drops offer a separate needle-free disease-modification pathway.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (allergy shots) | |||||
SLIT drops (off-label) | |||||
Pharmacotherapy |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
For patients who meet criteria 1 and 2 but cannot sustain the traditional 3-5 year weekly-clinic commitment that drives the 23.9% never-return cliff per Tkacz 2021, Curex delivers the allergy shot itself at home: a personalized SCIT serum sterile-compounded to USP <797> standards, prescribed and overseen by a board-certified allergist and self-administered as one weekly shot at home for $129/month. Your first dose and every dose change are supervised live over Zoom and a prescribed epinephrine auto-injector is confirmed on hand — preserving the disease-modification framework without the adherence-killing visit burden.
See if at-home shots are right for youFrequently asked questions
What are the medical criteria for getting allergy shots?
The AAAAI/ACAAI/JCAAI Practice Parameter (Cox L et al., JACI 2011;127[1 Suppl]:S1–S55) defines three candidacy criteria: (1) persistent allergic rhinitis, conjunctivitis, or asthma symptoms that remain moderate-to-severe despite optimized pharmacotherapy (intranasal corticosteroid plus second-generation antihistamine); (2) demonstrable IgE-mediated sensitization to a clinically relevant allergen, confirmed by skin-prick test or serum-specific IgE; and (3) willingness and capacity to commit to a 3–5 year course involving weekly injections during build-up (approximately 26–28 weeks) and every-2-to-4-week injections during maintenance, with mandatory 30-minute observation after every injection. Patients who meet all three are appropriate candidates; those who cannot sustain criterion 3 should discuss SLIT or pharmacotherapy alternatives.
Who should not get allergy shots?
Absolute and relative contraindications per Cox 2011 PP3 include: poorly controlled asthma (FEV1 <70% predicted) — the leading risk factor for fatal systemic reactions; beta-blocker use — blunts the epinephrine response needed to treat anaphylaxis; ACE inhibitor use (relative contraindication, especially for VIT); unstable cardiovascular disease; untreated active malignancy; severe immunodeficiency; severe psychiatric impairment that prevents the patient from communicating early reaction symptoms; and pregnancy initiation (SCIT initiation is contraindicated; continuation at established maintenance dose is generally safe). Patients with non-IgE-mediated rhinitis (vasomotor rhinitis, occupational non-allergic rhinitis) are also not candidates, as the mechanism of immunotherapy requires IgE-mediated sensitization.
Is allergy shots worth it for venom allergy?
For patients with Hymenoptera venom allergy — confirmed by positive skin test or serum-specific IgE to bee, wasp, yellow jacket, or hornet venom — allergy shots (VIT) are essentially always worth it when there has been a systemic sting reaction. Boyle RJ et al. (Cochrane 2012, PMID 23076950) found subsequent systemic sting reactions in 2.7% of treated patients versus 39.8% untreated — an absolute risk reduction of 37 percentage points. Golden DBK et al. (JACI 2005;115:439–447) states >95% protection. The alternative is potential fatal anaphylaxis on the next sting. The 3–5 year clinic-visit commitment is clearly justified by this dramatic risk reduction, and the answer to 'should I get venom allergy shots' is almost always yes for patients with confirmed venom allergy and prior systemic reaction.
Should children get allergy shots?
Children with moderate-to-severe allergic rhinitis and confirmed IgE sensitization are appropriate candidates for SCIT per Cox 2011 PP3, with the minimum age recommendation of approximately 5 years (based on ability to communicate early systemic-reaction symptoms). The strongest argument for initiating SCIT in children — beyond symptom relief — is asthma prevention. Jacobsen L et al. (Allergy 2007;62:943–948) documented OR 4.6 (95% CI 1.5–13.7) for remaining asthma-free at 10-year follow-up after 3 years of pediatric grass/birch SCIT. A child with allergic rhinitis who has a family history of asthma or who is showing early asthma symptoms is a particularly strong SCIT candidate. A pediatric allergist can assess whether the child's specific allergen profile and symptom burden justify the treatment.
What if I can't commit to weekly clinic visits for allergy shots?
If the weekly clinic visit schedule required for SCIT build-up (approximately 26–28 weeks of weekly injections) is not sustainably feasible, starting SCIT and dropping out is worse than not starting — 23.9% of US starters never return after their first injection (Tkacz 2021). Better alternatives for patients who meet criteria 1 and 2 but not criterion 3 include: FDA-approved SLIT-tablets for timothy grass (Grastek), 5-grass (Oralair), ragweed (Ragwitek), dust mite (Odactra), or Japanese cedar — taken daily at home after initial prescribing visit; or off-label SLIT-drops (supervised sublingual drops), which extend coverage to additional allergens without the injection-visit burden. Completing a SLIT course is more clinically valuable than starting SCIT and joining the 56.1% who do not reach maintenance.
Do allergy shots work if you only do them for one year?
A one-year course is unlikely to produce the durable post-treatment benefits documented in the evidence base. Durham SR et al. (NEJM 1999;341:468–475) specifically documented ≥3-year post-treatment remission after a 3–4 year course — and the study design was to test whether a completed course produces durable disease modification. Cox and Cohn (Ann Allergy Asthma Immunol 2007, PMID 17521025) found that courses shorter than approximately 2 years are associated with weaker durability and higher relapse. A one-year course may provide symptomatic benefit during the course, but the disease-modification and post-treatment remission outcomes documented in the Cochrane and Durham data are not achievable with an incomplete course. A board-certified allergist may continue treatment beyond the minimum if response is ongoing.
Can allergy shots help if I am sensitive to multiple allergens?
Polysensitized patients (those with IgE sensitization to multiple allergens) are appropriate SCIT candidates, but the treatment is more complex than for monosensitized patients. Calderón MA et al. (Cochrane 2007) analyses suggest monosensitized patients tend to respond more predictably. Multi-allergen SCIT vials — common in US practice — can dilute each component below its effective maintenance dose if too many allergens are included, potentially reducing per-component efficacy. A board-certified allergist experienced in SCIT can assess which allergens are clinically relevant (driving actual symptoms) versus which are incidental sensitizations, and select a vial composition that targets the dominant triggers without excessive dilution. Component-resolved diagnostics (CRD) — molecular allergy testing — can help distinguish genuine sensitization from cross-reactive sensitization.
Related Articles
Allergy Shots Pros and Cons – Decision Guide | Curex
Allergy shots pros and cons as a 3-step decision flow. Venom: 2.7% vs 39.8% sting reactions. Cons: 23.9% never return (Tkacz 2021). Thin evidence for cedar, non-Alternaria molds.
Read moreCat Allergy Shot for Humans | Curex SCIT Guide
This page covers cat allergy shots FOR HUMANS — SCIT with FDA-standardized Fel d 1 extract (10,000 BAU/mL). Not Cytopoint. Not Apoquel. ~72% symptom reduction in RCTs.
Read moreAllergy Shots Pros and Cons – Honest Review | Curex
Allergy shots pros: Cochrane SMD −0.73, durable remission, asthma prevention OR 4.6. Cons: 3–5 yr commitment, 23.9% never return, 0.1% systemic reaction rate.
Read moreAllergy Exposure Therapy: Safe vs Unsafe | Curex
Allergy exposure therapy = SCIT or SLIT: controlled escalating allergen doses under allergist care inducing tolerance. Unsupervised exposure is dangerous.
Read moreBenefits of Allergy Shots – Evidence Review | Curex
Benefits of allergy shots: symptom SMD −0.73 (Cochrane 2007), 80% medication reduction, pediatric asthma prevention OR 4.6, and ≥3-yr post-treatment remission.
Read moreDo Allergy Shots Work? Evidence & Honest Verdict | Curex
Do allergy shots work? Meta-analyses of 51 RCTs show 33-85% symptom reduction — but 20-50% of patients are low responders. Here's the honest evidence.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.